ASH 2012 Report – Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3… read more.